Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Abstract Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8 + cytotoxic T lymphocyte (CTL). Whether other steps along the PD‐1 signaling pathway can be targeted remains to be determined. Here, we report that methylene blue (MB), an FDA‐approved chemical for treating methemoglobinemia, potently inhibits PD‐1 signaling. MB enhances the cytotoxicity, activation, cell proliferation, and cytokine‐secreting activity of CTL inhibited by PD‐1. Mechanistically, MB blocks interaction between Y248‐phosphorylated immunoreceptor tyrosine‐based switch motif (ITSM) of human PD‐1 and SHP2. MB enables activated CTL to shrink PD‐L1 expressing tumor allografts and autochthonous lung cancers in a transgenic mouse model. MB also effectively counteracts the PD‐1 signaling on human T cells isolated from peripheral blood of healthy donors. Thus, we identify an FDA‐approved chemical capable of potently inhibiting the function of PD‐1. Equally important, our work sheds light on a novel strategy to develop inhibitors targeting PD‐1 signaling axis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even though SHP2 is important for inhibitory signaling of PD‐1 in most cases, T lymphocyte SHP2 deficiency can still be detrimental by reacting to the treatment of anti‐PD‐1 antibodies in vitro, thus revealing an alternate signaling pathway [284, 285].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [284]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, interfering with the interaction of SHP2 with programmed death-1 (PD-1) is a potent alternative to immuno-oncologic approaches aiming to block PD-1 with antibodies in several cancers [53].”
From The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling (2021) · cites this paper as [53]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Impressive clinical benefit was seen in a portion of cancer patients (Brahmer et al, 2010; Topalian et al, 2012; Powles et al, 2014).”
BackgroundSelf-citationBrahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961 · cited 2×
“Impressive clinical benefit was seen in a portion of cancer patients (Brahmer et al, 2010; Topalian et al, 2012; Powles et al, 2014).”
BackgroundSelf-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“In contrast, PD-1-deficient mice of C57BL/6 background develop and grow apparently normally, with autoimmune disease observed in late stage of their life (Nishimura et al, 1998, 1999).”
BackgroundMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381 · cited 1×
“Impressive clinical benefit was seen in a portion of cancer patients (Brahmer et al, 2010; Topalian et al, 2012; Powles et al, 2014).”
BackgroundFulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · cited 1×
“Unfortunately, PD-1 inhibitors currently used in clinic show severe, sometimes fatal, side effects (Johnson et al, 2016; Moslehi et al, 2018).”
BackgroundT cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Self-citationDecker, T., & Lohmann-Matthes, M.-L. (1988) · Journal of Immunological Methods · doi:10.1016/0022-1759(88)90310-9 · Cited by 1,359 · cited 1×
“Measuring lactate dehydrogenase (LDH) released by target tumor cells into medium is another accurate assay to determine CTL cytotoxicity (Decker & Lohmann-Matthes, 1988).”
MethodYokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · cited 17×
“Although SHP1 and SHP2 were earlier reported to be recruited by PD-1 to exert immunoinhibitory function, it is been confirmed that SHP2 is the main effecter (Yokosuka et al, 2012).”
BackgroundInfluential
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 160
Immune checkpoint inhibitors: breakthroughs in cancer treatment
Kong, X., Zhang, J., Chen, S., Wang, X., Xi, Q., Shen, H., & Zhang, R. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0055 · Cited by 204
“The core of PD-1’s inhibitory function lies in the ITSM-Y248 residue rather than the ITIM-Y223 residue 12 .”
BackgroundPan, J., Zhou, L., Zhang, C., Xu, Q., & Sun, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01038-3 · Cited by 129
“found that methylene blue prevented SHP2 from binding with Y248-phosphorylated PD-1 and therefore enhanced the tumorkilling effect of CTLs.(264) In addition, inducing the degradation and ubiquitination of SHP2 through its intracellular E3 ligase, FBXW7, was an outstanding approach that interrupted the downstream signa…”
BackgroundA comprehensive review of SHP2 and its role in cancer
Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119
Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy
Zhou, Z., Liu, Y., Song, W., Jiang, X., Deng, Z., Xiong, W., & Shen, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.004 · Cited by 118
Bojadzic, D., Alcazar, O., & Buchwald, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.600372 · Cited by 113
Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy
Song, Y., Wang, S., Zhao, M., Yang, X., & Yu, B. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02008 · Cited by 102
Akinsipe, T., Mohamedelhassan, R., Akinpelu, A., Pondugula, S. R., Mistriotis, P., Avila, L. A., & Suryawanshi, A. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1302587 · Cited by 88
Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy
Chen, M., Bie, L., & Ying, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115514 · Cited by 60
Fiebelkow, J., Guendel, A., Guendel, B., Mehwald, N., Jetka, T., Komorowski, M., Waldherr, S., Schaper, F., & Dittrich, A. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00770-7 · Cited by 53
“Additionally, interfering with the interaction of SHP2 with programmed death-1 (PD-1) is a potent alternative to immuno-oncologic approaches aiming to block PD-1 with antibodies in several cancers [53].”
BackgroundBobone, S., Pannone, L., Biondi, B., Šolman, M., Flex, E., Canale, V. C., Calligari, P. A., Faveri, C. D., Gandini, T., Quercioli, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01371 · Cited by 53
Protein post-translational modifications and tumor immunity: A pan-cancer perspective
Zhang, H., Yan, Q., Jiang, S., Hu, D., Lu, P., Li, S., Sandai, D. A., Zhang, H., Zhang, W., & Zhu, C. (2025) · Physics of Life Reviews · doi:10.1016/j.plrev.2025.10.001 · Cited by 44
Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway
Awadasseid, A., Wu, Y., & Zhang, W. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119813 · Cited by 40
Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy
Liu, S., Wang, H., Shao, X., Chen, H., Chao, S., Zhang, Y., Gao, Z., Yao, Q., & Zhang, P. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01966-4 · Cited by 40
“However, antibodies have disadvantages such as high production cost, poor oral bioavailability and low tumor penetration, so the development of non-antibody PD-1 inhibitors has become a research hotspot in recent years, including peptide inhibitors [53], non-peptide small molecule inhibitors [54, 55], nucleic acid dru…”
BackgroundZhang, H., Yang, L., Han, M., Han, Y., Jiang, Z., Zheng, Q., Dong, J., Wang, T., & Li, Z. (2024) · ACS Nano · doi:10.1021/acsnano.4c04553 · Cited by 39
Anti‐tumour potential of PD‐L1 / PD ‐1 post‐translational modifications
Zhou, S., Zhu, J., Xu, J., Gu, B., Zhao, Q., Luo, C., Gao, Z., Chin, Y. E., & Cheng, X. (2022) · Immunology · doi:10.1111/imm.13573 · Cited by 40
Combination Approaches to Target PD-1 Signaling in Cancer
Moore, E. K., Strazza, M., & Mor, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927265 · Cited by 34
“A study of methylene blue, a chemical with FDA approval for the treatment of methemoglobinemia, found that it inhibits PD-1 signaling by interfering with SHP2 binding, and interferes with tumor allograft growth (33).”
BackgroundTargeting SHP2 phosphatase in hematological malignancies
Kanumuri, R., Pasupuleti, S. K., Burns, S. S., Ramdas, B., & Kapur, R. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2066518 · Cited by 31
“It also showed anti-tumor activity in allograft and genetically engineered mice [73].”
BackgroundSmall-Molecule PROTACs for Cancer Immunotherapy
Liu, Z., Zhang, Y., Xiang, Y., & Kang, X. (2022) · Molecules · doi:10.3390/molecules27175439 · Cited by 31
Strategies for developing PD-1 inhibitors and future directions
Chen, W., Huang, Y., Pan, W., Xu, M., & Chen, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115113 · Cited by 30
Self-citationGSH responsive traditional clinical drugs probe for cancer cell fluorescence imaging and therapy
Xing, J., Gong, Q., Zou, R., Yao, J., Xiang, L., & Wu, A. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.107786 · Cited by 29
Small molecule agents for triple negative breast cancer: Current status and future prospects
Ou, Y., Wang, M., Xu, Q., Sun, B., & Jia, Y. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101893 · Cited by 31
“The small molecule chemical Methylene Blue (MB) can block PD-1 signal molecules to enhance the cytotoxicity of CD8 + cytotoxic T lymphocytes (CTL) and play an anti-tumor role [256].”
BackgroundPD ‐1: A critical player and target for immune normalization
Liu, X., Zhao, A., Xiao, S., Li, H., Li, M., Guo, W., & Han, Q. (2024) · Immunology · doi:10.1111/imm.13755 · Cited by 29
“Methylene blue has just been proposed as an agent that may prevent interactions between ITSM and SHP2, suppressing the PD-1 axis [103].”
BackgroundPerdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy
Jiang, M., Li, W., Zhu, C., Li, X., Zhang, J., Luo, Z., Qin, B., Du, Y., Luo, L., & You, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.031 · Cited by 26
SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function
Strazza, M., Adam, K. R., Lerrer, S., Straube, J., Sandigursky, S., Ueberheide, B. M., & Mor, A. (2021) · Inflammation · doi:10.1007/s10753-021-01437-8 · Cited by 27
Wang, M., Li, T., Ouyang, Z., Tang, K., Zhu, Y., Song, C., Sun, H., Yu, B., Ji, X., & Sun, Y. (2022) · iScience · doi:10.1016/j.isci.2022.104009 · Cited by 20
Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology
Liu, Z., Xiang, Y., Zheng, Y., & Kang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1027124 · Cited by 25
“Some small-molecule compounds that directly inhibit PD-1/PD-L1 interaction (11, 12) and its regulatory proteins, such as bromodomain and extraterminal domain (BET) (13, 14) and Src homology 2 domain containing protein tyrosine phosphatase (SHP2) (15, 16), as well as inhibitors of other immune checkpoints (CD47, CTLA-4…”
BackgroundCurrent studies and future promises of PD-1 signal inhibitors in cervical cancer therapy
Awadasseid, A., Zhou, Y., Zhang, K., Tian, K., Wu, Y., & Zhang, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114057 · Cited by 19
Tian, Y., Xin, S., Wan, Z., Dong, H., Liu, L., Fan, Z., Li, T., Peng, F., Xiong, Y., & Han, Y. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101978 · Cited by 18
“The Western blot analysis in this investigation was conducted according to the methods described earlier [26,27].”
MethodSelf-citationComplex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy
Scheiter, A., Lu, L., Gao, L. H., & Feng, G. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-013740 · Cited by 19
Li, N., Li, Z., Fu, L., Yan, M., Wang, Y., Yu, J., & Wu, J. (2022) · Stem Cells · doi:10.1093/stmcls/sxac037 · Cited by 17
Self-citationZheng, R., Huang, C., Zhou, H., Zhao, L., Li, Q., Chen, G., Zhao, L., & Li, S. (2024) · Aggregate · doi:10.1002/agt2.610 · Cited by 14
Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP-2
Li, W., Mei, W., Jiang, H., Wang, J., Li, X., Quan, L., Diao, Y., Ma, Y., Fan, S., Xie, Z., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2706-2 · Cited by 16
“Recently, methylene blue (MB), an FDA-approved compound for treating methemoglobinemia, was also reported to suppress PD-1 signaling by inhibiting the recruitment of SHP-2 by PD-1 (Fan et al., 2020).”
Self-citationZhou, Q., Yang, T., Yu, X., Li, B., Liu, J., Mao, Y., Guo, R., Feng, Z., Zhou, L., Zeng, G., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00200-y · Cited by 12
“In our experience, this method is readily applicable to measure the strength of interaction between proteins of transcription factors as shown in current work here, membrane proteins (Fan et al, 2020) and cytoplasmic proteins (Chen et al, 2020).”
Self-citationTargeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies
Salmond, R. J. (2024) · Cells · doi:10.3390/cells13030231 · Cited by 11
Liu, L., Lei, Y., Zheng, Z., Zhou, X., Chen, S., Zeng, G., Yu, L., Wang, P., & Chen, L. (2023) · Immunology · doi:10.1111/imm.13671 · Cited by 9
“We have shown that blocking the interaction between PD-1 and SHP2 is a valid target for developing PD-1 inhibitors, and that methylene blue is a potent PD-1 inhibitor [12].”
BackgroundInfluentialSelf-citationProtein tyrosine phosphatases: emerging role in cancer therapy resistance
Zhao, M., Shuai, W., Su, Z., Xu, P., Wang, A., Sun, Q., & Wang, G. (2024) · 癌症:英文版 · doi:10.1002/cac2.12548 · Cited by 11
Toral, K., Wuenschel, M. A., & Black, E. P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256416 · Cited by 8
Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic Opportunities
Jama, M., Overduin, M., & Barakat, K. (2025) · MedComm – Oncology · doi:10.1002/mog2.70028 · Cited by 8
Roozitalab, G., Abedi, B., İmani, S., Farghadani, R., & Kaboli, P. J. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10174-x · Cited by 7
“PD-L1 can also stimulate PD-1 phosphorylation at Y248 [68].”
Mei, Y., Hu, J., Cao, Y., Gao, X., Liao, W., Fu, C., Gao, Z., Tang, L., Zhang, J., & Wang, W. (2026) · Nano Today · doi:10.1016/j.nantod.2026.103049 · Cited by 6
Anti-Tumor Potential of Post-Translational Modifications of PD-1
Xi, X., & Zhao, W. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030136 · Cited by 7
“A variety of agents have been developed to treat tumors by targeting the pathway that inhibits the PD-1/SHP2 interaction [69–71].”
BackgroundTargeting SHP2 Sensitizes Papillary Thyroid Cancer Cells to MEK InhibitorsPreprint
Zhi, J., Yi, J., Xiukun, H., Wang, W., Yang, W., Hu, L., Huang, J., Guo, S., Ruan, X., Zheng, X., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3771278 · Cited by 6
Self-citationDeng, R., Zhang, L., Chen, S., Li, X., Xue, B., Li, H., Xu, Y., Tian, R., Liu, Q., Wang, L., et al. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105797 · Cited by 5
Chen, M., Zhang, L., Lin, W., Zhou, Z., Wang, Y., Wang, L., Gu, H., Li, J., & Xu, Z. P. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113889 · Cited by 4
Molecular recognition of ITIM/ITSM domains with SHP2 and their allosteric effect
Yan, C., Ouyang, W., Liu, L., Tang, L., Zhang, Z., Yue, X., Liang, L., Hu, J., & Luo, T. L. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp03923d · Cited by 4
Self-citationEmerging Therapeutic Approaches of SHP2-Targeted Modulators
Yang, X., Xiong, J., Yu, B., & Song, Y. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0348 · Cited by 4
Photodynamic Therapy Combined with Anticancer Drug Therapy in the Treatment of Malignant Neoplasms
Reshetov, I. V., Alyasova, A., Shpileva, O., Karalkin, P. A., Efendiev, K. T., Pominova, D. V., Loschenov, V. B., Ilyasova, D., Agakina, Y. S., Gilyadova, A. V., et al. (2026) · Cells · doi:10.3390/cells15090781 · Cited by 3
Zhang, Y., Zhu, C., Si, C., Lin, Y., Guo, Q., Zhou, H., & Yu, Z. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118708 · Cited by 3
Mohammadzadeh, S., Andalib, A., Khanahmad, H., & Esmaeil, N. (2023) · PubMed Central · Cited by 3
Unveiling Novel Targets in Lung Tumors for Enhanced Radiotherapy Efficacy: A Comprehensive Review
Muhammad, F. A., Adhab, A. H., Mahdi, M. S., Jain, V. D., Ganesan, S., Bhanot, D., Naidu, K. S., Kaur, S., Mansoor, A. S., Radi, U. K., et al. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70180 · Cited by 3
“The binding of PD ‐ L1 to PD ‐ 1 on T cells activates inhibitory signaling pathways, including the recruitment of SHP2 phosphatase, which dephosphorylates key signaling molecules in the TCR pathway, exhausting CTLs [140].”
Yan, Q., Qingqing, Z., Yu, S., & Zhang, W. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2598380 · Cited by 3
Zhu, C., Zhang, Y., Jin, Y., Yu, Y., Zhang, N., Yang, L., Gao, Y., Zhang, M., Shi, Y., Gao, Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03184 · Cited by 2
Zhuang, Y., Wang, L., Xie, C., Yang, R., Li, M., Dai, C., Di, Y., Yuan, M., Tong, T., Zhang, T., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c08006 · Cited by 2
Hepatology (Liver and Bile Duct)
Zhang, H. C., Wang, L. S., & Miller, E. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_7 · Cited by 2
Zhang, Z., Xu, A., Zhou, Q., Wen, F., Chen, F., Chen, H., Wang, H., Chen, L., Ju, Z., & Ge, Y. (2024) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szae065 · Cited by 1
“Compared with mice with mutated hKRAS , the EGFR (Del19) mice showed a much lower cancer burden and a longer process from initiation to early development of adenocarcinoma, 80,81 which is conducive to observing the occurrence of carcinoma and evaluating the safety of MSCs in tumorigenesis.”
Self-citationBiomimetic tumor microenvironment-responsive prodrug amplifies photoimmunotherapy via TLR2 agonist
Zhi, S., Huang, M., Liang, E. Y., Xu, L., Huang, L., & Cheng, K. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.04.020 · Cited by 1
Wu, F., Danzeng, Q., Wu, R., Shen, Y., & Shi, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835325 · Cited by 1
Coleman, J. L. (2020) · UEA Digital Repository (University of East Anglia)
Self-citationMechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
Yang, X. (2022) · BIO Web of Conferences · doi:10.1051/bioconf/20225501007
“There are three main functions of small molecule inhibitors: inhibiting PDL1/PD-1 interaction through BMS-8 and BMS-202 which are able to dissociate PD-1/PD-L1 complex [9], inhibiting PD-1/SHP2 interaction by phosphorylating Y248 in the cytoplasmic domain of hPD-1 with MB (lene blue), an FDA-approved chemical for trea…”
BackgroundBindingDB Entry 50016243: Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.
BindingDB (2023) · UC San Diego · doi:10.7270/q2x92g9p
SHP2 in Cancer: From Tumor Biology to Therapeutic Targeting
Jama, M., Overduin, M., & Barakat, K. (2026) · Medicinal Research Reviews · doi:10.1002/med.70119
Metadata
- Authors
- Fan, Z., Tian, Y., Chen, Z., Liu, L., Zhou, Q., He, J., Coleman, J., Dong, C., Li, N., Huang, J., Xu, C., Zhang, Z., Gao, S., Zhou, P., Ding, K., & Chen, L.
- Affiliations
- Jinan University (CN)
- Sun Yat-sen University Cancer Center (CN)
- University of East Anglia (GB)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Zhou, Penghui
- Ding, Ke
- Chen, Liang
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2020-05-11
- Volume
- 12
- Issue
- 6
- Pages
- e11571-e11571
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC7278553
- OpenAlex
- W3023016632
- Cited by
- 62
- References
- 51
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 16 · 2023: 7 · 2022: 17 · 2021: 6 · 2020: 3
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- NSF|Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81672309, 81972778, 31800723, 31701174)
- Guangzhou Research Project of Science and Technology for Citizen Health (201803010124)
- Science and Technology Program of Guangdong (2017B020227001)
- Fundamental Research Funds for the Central Universities (21618326)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- PD-1, SHP2, methylene blue, PD-1/PD-L1 axis, CD8+ cytotoxic T lymphocytes, lung cancer, immunotherapy, tumor allografts
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Antineoplastic Agents, Humans, T-Lymphocytes, Cytotoxic, CD8-Positive T-Lymphocytes, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.